Oncology Drugs
Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

Erman Akkus shared a post on X:

”Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity?

No

HR: 0.91 (95% CI 0.73–1.14) In patients with a history of CVD?

No

HR: 0.81 (95% CI 0.58–1.15)”

Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data

Authors: Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye.

Do adjuvant aromatase inhibitors increase risk of ischaemic cardiotoxicity in postmenopausal patients with early breast cancer?

aromatase inhibitor Bent Ejlertsen Breast Cancer cancer Denmark Erman Akkus Giulia Corn ischaemic cardiotoxicity Jan Wohlfahrt Kim Dalhoff Lars Køber Mads Melbye Maj-Britt Jensen Marie Lund OncoDaily Oncology postmenopausal patients The Lancet Oncology Tonny Petersen